First Wave to merge with ImmunogenX; Caliway raises $100M; New deals for Replay’s Syena
AcquisitionPhase 2Clinical Trial FailurePhase 3
First Wave BioPharma’s merger plans: The Florida biotech said it plans to merge with ImmunogenX, another gastrointestinal diseases company that is developing an oral candidate known as latiglutenase for celiac disease. After the deal closes, First Wave said it expects to announce that a global drugmaker is paying for the commercial rights to the drug candidate as well as new financing from undisclosed institutional investors. The Phase III trials are expected to begin in the second half of next year. — Kyle LaHucik
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.